A rapid method for the separation and analysis of leaked and liposomal entrapped phosphoramide mustard in plasma☆
References (16)
- et al.
J. Mol. Biol.
(1964) Cancer Treat. Rep.
(1989)- et al.
Pharmacol. Ther.
(1984) - et al.
Anal. Biochem.
(1990) - et al.
Biochim. Biophys. Acta
(1989) J. Clin. Pharmacol.
(1989)
There are more references available in the full text version of this article.
Cited by (8)
Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: Pharmacokinetics in mice
2005, Methods in EnzymologyCitation Excerpt :Presently, many anthracycline molecules are in clinical trials for treatment of several cancers. Efforts are being made to develop reliable methods for the delivery of anthracycline molecules, such as the use of liposomes as carrier systems (Bellott et al., 2001; Chonn et al., 1991; Druckman et al., 1989; Mayer and St.-Onge, 1995; Srigritsanapol and Chan, 1994; Thies et al., 1990). Several factors contribute to the complexity of the pharmacokinetics of liposome-entrapped drugs.
The (ir)relevance of plasma protein binding of anticancer drugs
2001, Netherlands Journal of MedicineSimple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography
2000, Journal of Chromatography B: Biomedical Sciences and ApplicationsPoly(methacrylic acid)-induced liposome aggregation for measuring drug entrapment
1995, Analytical BiochemistryResearch Progress of Analysis Methods in vivo for Anti-tumor Drug Liposomes
2024, Chinese Pharmaceutical Journal
- ☆
Presented in part at the Analysis and Pharmaceutical Quality Section of the Eighth Annual American Association of Pharmaceutical Scientists Meeting, November 1993, Orlando, Florida, USA.
- 1
College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Copyright © 1994 Published by Elsevier B.V.